Under physiological conditions, the kidneys contribute to
glucose homoeostasis by producing
glucose by gluconeogenesis and preventing
glucose loss in urine. The
glucose filtered by the glomeruli is completely reabsorbed in the renal proximal tubule. Renal gluconeogenesis produces 25% of the circulating
glucose in the postabsorptive state, while the amount of
glucose reabsorbed by the kidneys largely exceeds the quantity synthesized by kidney gluconeogenesis.
Sodium-glucose cotransporter type 2 (SGLT-2) and
glucose transporter 2 (GLUT2) carry out more than 90% of renal
glucose uptake. In diabetes, both gluconeogenesis and renal
glucose reabsorption are increased. The augmentation of
glucose uptake in diabetes is due to the overexpression of renal
glucose transporters SGLT-2 and GLUT2 in response to the increase in expression of transcription activator hepatic nuclear factor 1-alpha (HNF1α). The rise in
glucose uptake contributes to hyperglycaemia and induces glomerular hyperfiltration by increasing
sodium and water reabsorption in the proximal tubule that, in turn, modifies urine flux at the macula densa.
SGLT-2 inhibitors improve glycaemic control and prevent renal hyperfiltration in diabetes. Loss of SGLT-2 transporter function is a benign state characterized by
glycosuria. In contrast, mutations of other
glucose transporters expressed in the kidney are responsible for severe disorders.